<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04037514</url>
  </required_header>
  <id_info>
    <org_study_id>IBUPAR-TRIAL</org_study_id>
    <nct_id>NCT04037514</nct_id>
  </id_info>
  <brief_title>Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus</brief_title>
  <acronym>IBUPAR</acronym>
  <official_title>Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Máximo Vento Torres</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Clinical Research Network - CAIBER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, double-blind clinical trial, which will evaluate the efficacy of iv paracetamol
      versus standard treatment with ibuprofen in the closure of patent ductus arteriosus in the
      preterm newborn. Secondarily, we intend to compare the safety of both treatments, increase
      our knowledge about the pharmacokinetics, pharmacodynamics and pharmacogenetics of
      paracetamol and ibuprofen in the neonatal period and make a pharmacoeconomic assessment of
      the use of both drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Those newborns ≤ 30 weeks of gestational age who are diagnosed in the first 2 weeks of
      hemodynamically significant ductus arteriosus and who do not meet any exclusion criteria will
      be eligible to participate in the study.

      The PARACETAMOL group will receive intravenous doses of 15 mg/kg administered every 6h for 3
      days (up to a maximum of 2 courses, i.e. 6 days). The IBUPROFEN group (control group) will
      receive the usual treatment, this is an initial dose of 10 mg/kg followed by 5 mg/kg
      intravenously at 24 and 48 hours after the first (all three doses are considered a treatment
      course), up a maximum of 2 courses).

      A daily echocardiographic control will be performed to evaluate the closure of the ductus. If
      the ductus remains open and with significant clinical repercussion after completing a 3-day
      course of treatment, another batch of 3 doses of the same treatment will be administered. If
      medical treatment fails after two courses (6 days), the possibility of administering a batch
      of Ibuprofen at usual doses in both groups with the intention of offering standard treatment
      to all patients will be considered. Once the medical treatment with both drugs is completed
      if the ductus remains significant, the surgical closure will be carried out.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of closure of the hsPDA after treatment with paracetamol (experimental drug) versus ibuprofen (control drug).</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>It will include the closure rate after the first course of treatment, considered as ductus diameter &amp;lt; 1 mm monitored by echocardiography performed by a pediatric cardiology specialist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for a second course of treatment</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closure rate after two treatment courses</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue treatment after two courses of treatment</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reopening rate after closure</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closing rate after reopening</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required until closing</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical ligation</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early complications</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
    <description>oliguria, renal failure, necrotizing enterocolitis, intraventricular hemorrhage, hyperbilirubinemia, gastrointestinal bleeding or perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of late complications</measure>
    <time_frame>from randomization until 2 years</time_frame>
    <description>bronchopulmonary dysplasia, periventricular leukomalacia, necrotizing enterocolitis, retinopathy of the newborn, neurodevelopmental assessment, sepsis, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics model of paracetamol in the context of hsPDA: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Relation of effectiveness/adverse reactions to serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics model of paracetamol in the context of hsPDA: Minimum Plasma Concentration [Cmin]</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Relation of effectiveness/adverse reactions to serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics model of paracetamol in the context of hsPDA: Area Under the Curve [AUC])</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Relation of effectiveness/adverse reactions to serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics model of paracetamol in the context of hsPDA: urine metabolites</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Quantification of metabolites in urine and its relationship with drug elimination/metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics of paracetamol</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Genetic polymorphisms in TFAP2B, TGFBR2, EPAS1, MD-2 and GM2A genes related to efficacy/occurrence of adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Price-effectiveness ratio. Cost-effectiveness analysis depending on the efficiency obtained in the treatment.</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotoxicity mesured by %DNA damage</measure>
    <time_frame>from randomization until discharge, an average of 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Patent Ductus Arteriosus After Premature Birth</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Intravenous paracetamol 15 mg/kg/6h</description>
    <arm_group_label>Paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed consent of parents/guardians

          -  Gestacional Age ≤30 weeks

          -  Postnatal age ≤ 2 weeks

          -  Need for ventilatory support

          -  Born in participating hospital/arrival to them within the period of application of the
             treatment

          -  1 st episode of hemodynamically significant Patent Ductus Arteriosus

        Exclusion Criteria:

          -  Major congenital malformations or chromosomopathies

          -  Refusal to participate and / or sign the informed consent.

          -  Impossibility or erroneous randomization

          -  Participation in another clinical trial with drugs

          -  Diuresis less than 1 ml / kg / h for 8 h prior to treatment

          -  Greater than 1.8 mg / dl Creatinine

          -  Platelets below 50,000 / uL

          -  Active bleeding (tracheal, gastrointestinal and renal)

          -  Intraventricular hemorrhage recently (48h) (grades 3-4)

          -  Severe hyperbilirubinemia

          -  Liver failure or severe coagulopathy

          -  Active necrotizing enterocolitis or intestinal perforation

          -  Septic shock

          -  Imminent death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maximo Vento Torres, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Aguar Carrascosa, PhD, MD</last_name>
    <phone>0034 961245686</phone>
    <email>maraca@alumni.uv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana García Robles, PharmD</last_name>
    <phone>0034 961245686</phone>
    <email>garcia.anarob@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José Párraga Quiles, MD</last_name>
      <email>majopaqui@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Costa Romero, MD</last_name>
      <email>marta.costar78@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Materno-Infantil (Hospital Regional Carlos Haya) Málaga:</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Mar Serrano Martín, MD</last_name>
      <email>mmarser@live.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Aguar Carrasacosa, PhD, MD</last_name>
      <email>maraca@alumni.uv.es</email>
    </contact>
    <investigator>
      <last_name>Ana García Robles, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013 Nov 4;8(11):e77888. doi: 10.1371/journal.pone.0077888. eCollection 2013.</citation>
    <PMID>24223740</PMID>
  </reference>
  <reference>
    <citation>Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011 Dec;128(6):e1618-21. doi: 10.1542/peds.2011-0359. Epub 2011 Nov 7.</citation>
    <PMID>22065264</PMID>
  </reference>
  <reference>
    <citation>Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, Canpolat FE, Dilmen U. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. 2014 Mar;164(3):510-4.e1. doi: 10.1016/j.jpeds.2013.11.008. Epub 2013 Dec 18.</citation>
    <PMID>24359938</PMID>
  </reference>
  <reference>
    <citation>Yang B, Gao X, Ren Y, Wang Y, Zhang Q. Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: A randomized controlled trial. Exp Ther Med. 2016 Oct;12(4):2531-2536. Epub 2016 Sep 6.</citation>
    <PMID>27698754</PMID>
  </reference>
  <reference>
    <citation>Dash SK, Kabra NS, Avasthi BS, Sharma SR, Padhi P, Ahmed J. Enteral paracetamol or Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial. Indian Pediatr. 2015 Jul;52(7):573-8.</citation>
    <PMID>26244949</PMID>
  </reference>
  <reference>
    <citation>Sancak S, Gokmen Yildirim T, Topcuoglu S, Yavuz T, Karatekin G, Ovali F. Oral versus intravenous paracetamol: which is better in closure of patent ductus arteriosus in very low birth weight infants? J Matern Fetal Neonatal Med. 2016;29(1):135-9. doi: 10.3109/14767058.2014.989829. Epub 2014 Dec 23.</citation>
    <PMID>25471090</PMID>
  </reference>
  <reference>
    <citation>El-Khuffash A, Jain A, Corcoran D, Shah PS, Hooper CW, Brown N, Poole SD, Shelton EL, Milne GL, Reese J, McNamara PJ. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatr Res. 2014 Sep;76(3):238-44. doi: 10.1038/pr.2014.82. Epub 2014 Jun 18.</citation>
    <PMID>24941212</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigacion Sanitaria La Fe</investigator_affiliation>
    <investigator_full_name>Máximo Vento Torres</investigator_full_name>
    <investigator_title>Scientific Director Health Research Institute La Fe</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

